Authors: Roisin Conneely
LMTX®, an experimental tau aggregation inhibitor developed by TauRx Theraputics Ltd, has demonstrated promise for Alzheimer’s disease (AD) in its second Phase III trial. The results suggest that the drug may be effective in doses as low as 4mg, but only when used as a monotherapy.
The study, published in the Journal of Alzheimer’s Diseases, explored drug effectiveness in 800 patients with mild AD, over a period of 18 months.
Restricted Content / Members Only